Bionomics Investor Presentation Deck
Bionomics Highlights
Targeting Social Anxiety Disorder (SAD) and PTSD, and cognitive dysfunction associated with Alzheimer's
disease, schizophrenia and other CNS disorders
Lead asset: BNC210 - a negative allosteric modulator of the a7 Nicotinic Acetylcholine receptor
alı
BNC210:
✓ Clinical PoC in GAD¹ and FDA Fast Track designation for acute Social Anxiety Disorder (SAD)
✓ In Phase 2 PREVAIL trial for acute treatment in SAD
In Phase 2b ATTUNE trial with Fast Track designation from FDA for PTSD
Partnerships & Collaborations:
✓ Strategic partnership with Merck for treatment of cognitive deficits in Alzheimer's and other CNS disorders
✓ MOU with EmpathBio for feasibility assessment of EMP-01 (MDMA derivative) & BNC210 for PTSD treatment
✓ Pipeline of partnering candidates targeting potassium (Kv) and sodium (Nav) ion channels
✓ Well-capitalized balance sheet and cash runway beyond multiple potential near term value-driving milestones
✓ BNC210 IP coverage extending to late 2030's
Bionomics PoC = Proof of Concept
GAD= Generalized Anxiety Disorder
PTSD = Post-Traumatic Stress Disorder
1. Wise et al 2020, Biological Psychiatry; Perkins et al 2021, Molecular Psychiatry
3View entire presentation